Evidence map›Paper›PMID 28341976›Full record

ArticleMolecular imaging and biology2017

Development and Evaluation of User-Friendly Single Vial DOTA-Peptide Kit Formulations, Specifically Designed for Radiolabelling with

Deidré Prince, Daniel Rossouw, Claudia Davids, Sietske Rubow

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Cold Kit Labeling: The Future ofFrontiers in medicine · 2022
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Deidré PrinceRadionuclide Production Department, iThemba LABS, PO Box 722, Somerset West, 7129, South Africa. deidre@tlabs.ac.za.
Daniel RossouwRadionuclide Production Department, iThemba LABS, PO Box 722, Somerset West, 7129, South Africa.
Claudia DavidsRadionuclide Production Department, iThemba LABS, PO Box 722, Somerset West, 7129, South Africa.
Sietske RubowNuclear Medicine Division, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study was aimed to develop single vial 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide kits to be used with fractionated eluates from a SnO PROCEDURES: Kits were formulated with 35 μg DOTA-Tyr

resultsThe quality of the kits was found to be suitable over a 1-year storage period (pH, sterility, endotoxin content, radiolabelling efficiency and radiochemical yields of

conclusionThe single vial kit formulations met the quality release specifications for human administration and appear to be highly advantageous over using peptide stock solutions in terms of stability and user-friendliness.

Indexed as

Reagent Kits, DiagnosticChromatography, High Pressure LiquidGermaniumHydrogen-Ion ConcentrationOctreotideOrganometallic CompoundsRadiopharmaceuticalsTin Compounds68Ga-DOTA-octreotideGermaniumOctreotideOrganometallic CompoundsRadiopharmaceuticalsReagent Kits, Diagnosticstannic oxideTin Compounds68Ga eluateDOTA-peptidesRadiochemical yieldsRadiolabelling efficiencySingle vial kitSnO2-based 68Ge/68Ga generator

Identifiers

PMID28341976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.